Four insights:
1. The study found that 80 percent of patients suffering from chronic back pain and treated with DTM reported at least 50 percent pain relief, compared with 51 percent of patients treated with traditional SCS.
2. Sixty-three percent of patients treated with DTM reported pain relief of 80 percent or greater, compared to 26 percent treated with traditional SCS.
3. Administered via Medtronic’s Intellis platform, DTM SCS therapy is a programming option used to treat patients with chronic pain.
4. DTM was developed by Stimgenics, which was acquired by Medtronic on Jan. 8.
More articles on devices:
Bundled payments in spine: 12 key thoughts for 2020
Should pain management physicians perform endoscopic spine surgery? 8 spine specialists discuss
Medtronic CEO Omar Ishrak becomes Intel board chairman: 4 details
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
